1. Home
  2. BATRK vs ADPT Comparison

BATRK vs ADPT Comparison

Compare BATRK & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atlanta Braves Holdings Inc. Series C

BATRK

Atlanta Braves Holdings Inc. Series C

HOLD

Current Price

$47.62

Market Cap

2.8B

Sector

Industrials

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.47

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BATRK
ADPT
Founded
1991
2009
Country
United States
United States
Employees
1610
N/A
Industry
Broadcasting
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.3B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
BATRK
ADPT
Price
$47.62
$14.47
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$60.00
$17.78
AVG Volume (30 Days)
270.7K
1.9M
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
$12.40
$3.98
Revenue Next Year
$8.54
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
N/A
54.77
52 Week Low
$37.74
$6.77
52 Week High
$47.16
$20.76

Technical Indicators

Market Signals
Indicator
BATRK
ADPT
Relative Strength Index (RSI) 78.46 52.20
Support Level $38.57 $12.22
Resistance Level N/A $17.72
Average True Range (ATR) 0.92 0.88
MACD 0.35 0.15
Stochastic Oscillator 94.78 68.06

Price Performance

Historical Comparison
BATRK
ADPT

About BATRK Atlanta Braves Holdings Inc. Series C

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: